priors.science/reviews/antimicrobial-resistance-novel-antibiotics

Antimicrobial Resistance Novel Antibiotics

The current evidence on 16 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

16claims tracked
101primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
6 Established · 7 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableAntimicrobial resistance is responsible for approximately 1.27 million deaths globally per year as a direct cause, with an additional 3.7 million deaths attributable, making it among the leading infectious causes of global mortality.Amr Burden EpidemiologyEstablished93%7
StableAntimicrobial stewardship programmes (ASPs) in hospital settings reduce inappropriate antibiotic use, length of stay, and Clostridioides difficile infection rates without increasing mortality, as demonstrated in multiple systematic reviews and implementation studies.Stewardship PreventionEstablished93%7
StableCarbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA) represent the highest-priority critical threats to human health as designated by the WHO and CDC, with clinical mortality rates of 40-70% in bloodstream infections.Amr Burden EpidemiologyEstablished92%7
StableCeftazidime-avibactam is effective against KPC- and OXA-48-producing Enterobacterales and is superior to colistin-based regimens for carbapenem-resistant infections, but lacks activity against metallo-beta-lactamase (MBL)-producing organisms (NDM, VIM, IMP).Novel Antibiotics Gram NegativeEstablished92%7
StableExtended-spectrum beta-lactamase (ESBL)-producing Enterobacterales have reached endemic prevalence in community and hospital settings globally, with ESBL-E. coli rates exceeding 10% in most European countries and 50% in parts of Asia and sub-Saharan Africa.Beta Lactam ResistanceEstablished91%6
StableOritavancin and dalbavancin (long-acting lipoglycopeptides) provide single-dose or once-weekly treatment options for MRSA skin and soft tissue infections, with non-inferior efficacy to intravenous vancomycin and improved feasibility for outpatient management.Novel Antibiotics Gram PositiveEstablished91%6
StableColistin-based combination regimens for carbapenem-resistant organisms are associated with significant nephrotoxicity and have been largely superseded by newer beta-lactam/beta-lactamase inhibitor combinations where these are active, but colistin remains the last-resort option where novel agents are unavailable.Combination StrategiesLikely77%6
StableCeftolozane-tazobactam and imipenem-cilastatin-relebactam are active against multidrug-resistant Pseudomonas aeruginosa, including strains resistant to piperacillin-tazobactam and carbapenems, but are not effective against MBL-producing strains.Novel Antibiotics Gram NegativeLikely77%6
StableDaptomycin and linezolid remain effective first-line options for vancomycin-resistant Enterococcus (VRE) and MRSA infections, with daptomycin non-susceptibility emerging in VRE as a clinical concern in patients receiving prolonged therapy.Novel Antibiotics Gram PositiveLikely77%6
StableCarbapenemase-producing organisms (CPO) including KPC, OXA-48, NDM, and VIM enzymes are globally distributed, with plasmid-mediated horizontal transfer the dominant mechanism of carbapenem resistance spread.Beta Lactam ResistanceLikely76%6
StableCefiderocol (a siderophore cephalosporin) is active against most carbapenem-resistant Gram-negative bacteria including MBL-producers and CRAB, but CREDIBLE-CR trial data showed higher mortality versus best available therapy in A. baumannii infections, limiting its use in that pathogen.Emerging ApproachesLikely76%7
StableAztreonam-avibactam is active against metallo-beta-lactamase (NDM, VIM, IMP)-producing Enterobacterales and provides coverage for organisms resistant to ceftazidime-avibactam, representing the first beta-lactam/beta-lactamase inhibitor combination with MBL activity.Novel Antibiotics Gram NegativeLikely76%6
StableInfection prevention and control measures (contact precautions, environmental decontamination, hand hygiene compliance) reduce transmission of MDR organisms in healthcare settings, with bundle approaches more effective than single interventions.Stewardship PreventionLikely76%6
StableCombination therapy (ceftazidime-avibactam plus aztreonam) for NDM-producing organisms is supported by in vitro synergy data and observational clinical data, but randomised trial evidence comparing combination versus monotherapy regimens for CRE infections is limited.Combination StrategiesUncertain51%6
StableBacteriophage therapy has demonstrated proof-of-concept in compassionate use cases for life-threatening MDR infections refractory to antibiotics, but lacks Phase 3 randomised trial evidence for any approved indication.Emerging ApproachesUncertain51%6
StableOmadacycline and eravacycline (novel tetracyclines) provide activity against MDR Gram-negative and Gram-positive organisms including CRAB and ESBL-producers, but clinical trial evidence for severe infections (bacteraemia, pneumonia) is limited compared to ABSSSI and intra-abdominal infection data.Emerging ApproachesUncertain51%6
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic